{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:08:49Z","timestamp":1784862529554,"version":"3.55.0"},"reference-count":29,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Objective\u2003The objective of this study was to evaluate the clinical utility of gallium-68 [68Ga] prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) with rising prostate-specific antigen (PSA) levels in prostate cancer diagnosis.<\/jats:p><jats:p>\n          Methods\u2003This is a retrospective, single-center, observational cross-sectional study, which is provided after ethics committee clearance, from May 2, 2022 to June 25, 2022. Study includes sample size of 50 patients with prostate adenocarcinoma with varying PSA levels and Gleason score of 6 to 9 who underwent [68Ga] PSMA PET\/CT scan. The patients included in this study underwent PET\/CT scan on uMI550 (United Imaging Healthcare, Shanghai, China).<\/jats:p><jats:p>\n          Results\u2003All patients were divided into three groups based on PSA levels in ng\/mL as: PSA \u2264 0.2 (8%), 0.2\u2009&lt;\u2009PSA \u2264 1 (10%), 1\u2009&lt;\u2009PSA \u2264 3 (8%), 3\u2009&lt;\u2009PSA \u2264 10 (18%), and PSA\u2009&gt;\u200910 (56%). Among 50 scans, at least one PSMA avid lesion was visualized in 41 scans (78.9%). These scans were considered positive and included in this study, rest of the scans had insignificant PSMA uptake and were considered negative. [68Ga] PSMA PET\/CT detection rates were 75.0, 20.0, 50.0, 88.90, and 89.3% in patients with PSA \u2264 0.2, 0.2\u2009&lt;\u2009PSA \u2264 1, 1\u2009&lt;\u2009PSA \u2264 3, 3\u2009&lt;\u2009PSA \u2264 10, and PSA\u2009&gt;\u200910, respectively. In addition to prostate bed, lesions were also visualized in lymph nodes (32%), liver (2%), skeleton (28%), and thorax (6%). Considering lesions in the prostate bed a significant direct correlation was detected between maximal standardized uptake value (SUVmax) and PSA value (p\u2009=\u20090.03).<\/jats:p><jats:p>\n          Discussion\u2003PSMA PET\/CT has been demonstrated to be an effective method for identifying both low-grade Gleason score tumors and low PSA levels. The study provides support for the use of [68Ga] PSMA PET\/CT in conjunction with PSA levels for the evaluation of prostate cancer, including local recurrence and distant metastases.<\/jats:p><jats:p>\n          Conclusion\u2003The findings of this study indicate that PSMA PET\/CT is an effective method for diagnosing prostate cancer, as it allows for the detection of high SUVmax values in pathological tissues. Furthermore, high sensitivity and detection rates are noted with PSMA PET\/CT scan even in cases where PSA levels were low. Therefore, this study demonstrates that [68Ga] PSMA PET\/CT is beneficial for the early detection of prostate cancer and the prediction of treatment outcomes.<\/jats:p>","DOI":"10.1055\/s-0045-1804894","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:12:56Z","timestamp":1740701576000},"page":"144-154","source":"Crossref","is-referenced-by-count":3,"title":["Detection Accuracy of [68Ga] PSMA PET\/CT with Rising PSA in Prostate Cancer"],"prefix":"10.1055","volume":"24","author":[{"given":"Parul","family":"Mohan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Mahajan Imaging and Labs, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Wadhwa","sequence":"additional","affiliation":[{"name":"Central Research Institute, Shanghai United Imaging Healthcare, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Mahajan Imaging and Labs, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Central Research Institute, Shanghai United Imaging Healthcare, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Aringhieri","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine & PET\/CT, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Cioni","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine & PET\/CT, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"107932","DOI":"10.1016\/j.pharmthera.2021.107932","article-title":"Prostate cancer biomarkers: from diagnosis to prognosis and precision-guided therapeutics","volume":"228","author":"M Adamaki","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"08","key":"ref3","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/1055-9965.EPI-10-0437","article-title":"Global patterns of cancer incidence and mortality rates and trends","volume":"19","author":"A Jemal","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"C Mattiuzzi","year":"2019","journal-title":"J Epidemiol Glob Health"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/aja.2008.19","article-title":"Prostate cancer: diagnosis and staging","volume":"11","author":"N Borley","year":"2009","journal-title":"Asian J Androl"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"a030601","DOI":"10.1101\/cshperspect.a030601","article-title":"Molecular biomarkers in the clinical management of prostate cancer","volume":"8","author":"A M Udager","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.20892\/j.issn.2095-3941.2018.0288","article-title":"68Gallium-labelled PSMA-PET\/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy","volume":"16","author":"J SH Tan","year":"2019","journal-title":"Cancer Biol Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"831429","DOI":"10.3389\/fonc.2022.831429","article-title":"PSMA PET in imaging prostate cancer","volume":"12","author":"I Tsechelidis","year":"2022","journal-title":"Front Oncol"},{"issue":"01","key":"ref9","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"D A Silver","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/JU.0000000000002457","article-title":"Imaging prostate cancer: clinical utility of prostate-specific membrane antigen","volume":"207","author":"D Kuppermann","year":"2022","journal-title":"J Urol"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13550-022-00881-3","article-title":"Comparison of 68Ga-PSMA PET\/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer","volume":"12","author":"C Zhou","year":"2022","journal-title":"EJNMMI Res"},{"key":"ref12","volume-title":"Prostate Specific Antigen","author":"M K David"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1590\/S1677-55382009000500003","article-title":"Prostatic specific antigen for prostate cancer detection","volume":"35","author":"L Nogueira","year":"2009","journal-title":"Int Braz J Urol"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.semnuclmed.2004.06.004","article-title":"Positron emission tomography for prostate, bladder, and renal cancer","volume":"34","author":"H Sch\u00f6der","year":"2004","journal-title":"Semin Nucl Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"k3519","DOI":"10.1136\/bmj.k3519","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"D Ilic","year":"2018","journal-title":"BMJ"},{"key":"ref16","volume-title":"Prostate Specific Antigen","author":"M K David"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"105016","DOI":"10.1088\/1361-6560\/abfb17","article-title":"PET image reconstruction with deep progressive learning","volume":"66","author":"Y Lv","year":"2021","journal-title":"Phys Med Biol"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.2967\/jnumed.119.238071","article-title":"Multiphasic 68Ga-PSMA PET\/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1\u2009ng\/mL: a prospective study of 135 patients","volume":"61","author":"M Beheshti","year":"2020","journal-title":"J Nucl Med"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4103\/0972-3919.202255","article-title":"Clinical utility of gallium-68 PSMA PET\/CT scan for prostate cancer","volume":"32","author":"K G Kallur","year":"2017","journal-title":"Indian J Nucl Med"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00259-018-4067-3","article-title":"68Ga-PSMA PET\/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients","volume":"45","author":"P Caroli","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"07","key":"ref23","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00259-018-3970-y","article-title":"Optimal time-point for 68Ga-PSMA-11 PET\/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?","volume":"45","author":"M Beheshti","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","article-title":"68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour","volume":"44","author":"C Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"M Eiber","year":"2015","journal-title":"J Nucl Med"},{"issue":"08","key":"ref26","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","author":"A Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"06","key":"ref27","first-page":"580","article-title":"Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature","volume":"4","author":"C Y Yu","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","article-title":"Initial experience of 68Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy","volume":"69","author":"L Bud\u00e4us","year":"2016","journal-title":"Eur Urol"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.eururo.2015.12.051","article-title":"68Ga-PSMA positron emission tomography\/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer","volume":"70","author":"A Herlemann","year":"2016","journal-title":"Eur Urol"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of 68gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"T Maurer","year":"2016","journal-title":"J Urol"},{"issue":"22","key":"ref31","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0\u2009ng per milliliter","volume":"350","author":"I M Thompson","year":"2004","journal-title":"N Engl J Med"}],"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1804894.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:37:56Z","timestamp":1746571076000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1804894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":29,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,5,6]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1804894","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}